Steven Limentani
Overview
Explore the profile of Steven Limentani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
660
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loibl S, Huang C, Mano M, Mamounas E, Geyer Jr C, Untch M, et al.
NPJ Breast Cancer
. 2022 Sep;
8(1):106.
PMID: 36117201
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients....
2.
Bear H, Wan W, Robidoux A, Rubin P, Limentani S, White Jr R, et al.
J Surg Oncol
. 2018 Oct;
118(4):722.
PMID: 30295942
No abstract available.
3.
Bear H, Wan W, Robidoux A, Rubin P, Limentani S, White Jr R, et al.
J Surg Oncol
. 2017 Apr;
115(8):917-923.
PMID: 28407247
Objective: We hypothesized that the Oncotype Dx 21-gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers....
4.
Abraham J, Robidoux A, Tan A, Limentani S, Sturtz K, Shalaby I, et al.
Breast Cancer Res Treat
. 2015 Jul;
152(2):399-405.
PMID: 26126970
Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents...
5.
Burris 3rd H, Rugo H, Vukelja S, Vogel C, Borson R, Limentani S, et al.
J Clin Oncol
. 2010 Dec;
29(4):398-405.
PMID: 21172893
Purpose: The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2)-overexpressing cancer...
6.
Schiller J, Larson T, Ou S, Limentani S, Sandler A, Vokes E, et al.
J Clin Oncol
. 2009 Jul;
27(23):3836-41.
PMID: 19597027
Purpose: This phase II study evaluated efficacy and safety of single-agent axitinib, an oral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, in patients...
7.
Stinchcombe T, Lee C, Moore D, Rivera M, Halle J, Limentani S, et al.
J Thorac Oncol
. 2008 Nov;
3(11):1279-85.
PMID: 18978563
Background: We conducted a modified phase I/II trial investigating the incorporation of three-dimensional conformal thoracic radiation therapy (TCRT) into the treatment paradigm of induction and concurrent carboplatin and paclitaxel in...
8.
Richardson P, Briemberg H, Jagannath S, Wen P, Barlogie B, Berenson J, et al.
J Clin Oncol
. 2006 Jun;
24(19):3113-20.
PMID: 16754936
Purpose: To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of advanced multiple myeloma. Patients And Methods: Peripheral neuropathy was assessed in two phase II studies...
9.
Berenson J, Jagannath S, Barlogie B, Siegel D, Alexanian R, Richardson P, et al.
Cancer
. 2005 Oct;
104(10):2141-8.
PMID: 16206291
Background: Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. Methods: Bortezomib 1.0 or 1.3 mg/m2 was administered Days 1, 4, 8, and 11...